DV
Dividend Vision

AIDX — 20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. Common Stock (AIDX)

Total return is -97.7% over the past 0.5 years, 111.7 points behind SPY at 14.0%.

20/20 Biolabs, Inc. develops and commercializes AI-powered blood tests for early detection and prevention of cancers and chronic diseases, including its OneTest for Cancer and OneTest for Longevity products, and operates CLIAx, a CLIA laboratory serving overseas diagnostics companies. The company does not currently distribute dividends. This stock may appeal to investors seeking exposure to diagnostic technology and early-stage cancer detection innovation rather than current income.

AIDX key facts

Asset type
Stock
Asset class
Equity
Inception date
02/19/2026
Last close
$0.55
Market cap
$6,341,220
Average volume
228500.0
Beta
-0.425
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.49